Table 5 Cumulative percent of patients with AEs
From: Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease
| Â | Donepezil 23 mg/d | Donepezil 10 mg/d | ||||||
|---|---|---|---|---|---|---|---|---|
| Â | 1 week | 2 weeks | 4 weeks | Total duration | 1 week | 2 weeks | 4 weeks | Total duration |
Number (%) of subjects with at least 1 such AE | 289 (30.0) | 347 (36.0) | 444 (46.1) | 710 (73.7) | 57 (12.1) | 83 (17.6) | 124 (26.3) | 300 (63.7) |
Number (%) of subjects who discontinued due to AEs | 80 (8.3) | 98 (10.2) | 122 (12.7) | 179 (18.6) | 9 (1.9) | 16 (3.4) | 20 (4.2) | 37 (7.9) |
Vomiting | 68 (7.1) | 73 (7.6) | 77 (8.0) | 89 (9.2) | 5 (1.1) | 5 (1.1) | 5 (1.1) | 12 (2.5) |
Nausea | 92 (9.6) | 96 (10.0) | 100 (10.4) | 114 (11.8) | 6 (1.3) | 7 (1.5) | 9 (1.9) | 16 (3.4) |
Diarrhea | 34 (3.5) | 44 (4.6) | 57 (5.9) | 80 (8.3) | 8 (1.7) | 11 (2.3) | 12 (2.5) | 25 (5.3) |
Dizziness | 26 (2.7) | 28 (2.9) | 35 (3.6) | 47 (4.9) | 3 (0.6) | 6 (1.3) | 8 (1.7) | 16 (3.4) |
Headache | 18 (1.9) | 22 (2.3) | 30 (3.1) | 41 (4.3) | 1 (0.2) | 2 (0.4) | 5 (1.1) | 15 (3.2) |